首页|重组人脑利钠肽联合丹参川芎嗪注射液治疗慢性心力衰竭的效果研究

重组人脑利钠肽联合丹参川芎嗪注射液治疗慢性心力衰竭的效果研究

扫码查看
目的 分析慢性心力衰竭(CHF)采用重组人脑利钠肽(rhBNP)联合丹参川芎嗪注射液(SMLI)治疗取得的效果.方法 86 例CHF患者,参照随机数字表法分为对照组和研究组,每组 43 例.对照组患者采用常规对症治疗与rhBNP治疗,研究组患者在对照组的基础上联用SMLI治疗.对比两组疗效、心功能指标(左心室收缩末期内径、左室射血分数、左心室舒张末期内径)、心力衰竭(心衰)血清学指标(N末端脑钠肽前体、心肌肌钙蛋白I)及不良反应发生情况.结果 研究组总有效率 95.35%较对照组的 79.07%高(P<0.05).研究组治疗后左心室收缩末期内径(44.65±4.50)mm、左心室舒张末期内径(51.67±2.79)mm小于对照组的(48.70±5.05)、(54.55±2.62)mm,左室射血分数(44.44±4.80)%高于对照组的(39.74±3.65)%(P<0.05).研究组治疗后N末端脑钠肽前体(828.34±179.40)ng/L、心肌肌钙蛋白I(2.60±0.69)μg/L低于对照组的(970.25±112.32)ng/L、(4.50±0.75)μg/L(P<0.05).两组不良反应发生率对比,结果未见差异性(P>0.05).结论 CHF患者采用rhBNP与SMLI联合治疗疗效确切,能够有效改善患者的心功能,调节心衰血清学指标,安全性较为理想,具有临床应用价值.
Study on effect of recombinant human brain natriuretic peptide combined with salviae miltiorrhizae and ligustrazine hydrochloride injection on chronic heart failure
Objective To analyze the effect of recombinant human brain natriuretic peptide(rhBNP)combined with salviae miltiorrhizae and ligustrazine hydrochloride injection(SMLI)on chronic heart failure(CHF).Methods 86 patients with CHF were divided into a control group and a study group according to random number table method,with 43 cases in each group.The control group was treated with conventional symptomatic treatment and rhBNP,and the study group was treated with SMLI on the basis of the control group.Both groups were compared in terms of efficacy,cardiac function indexes(left ventricular end-systolic diameter,left ventricular ejection fraction,left ventricular end-diastolic diameter),serological indexes of heart failure(N-terminal pro-brain natriuretic peptide,cardiac troponin I)and adverse reactions.Results The study group had higher total effective rate of 95.35%than 79.07%in the control group(P<0.05).After treatment,the study group had left ventricular end-systolic diameter of(44.65±4.50)mm and left ventricular end-diastolic diameter of(51.67±2.79)mm,which were smaller than(48.70±5.05)and(54.55±2.62)mm in the control group;the study group had higher left ventricular ejection fraction of(44.44±4.80)%than(39.74±3.65)%in the control group(P<0.05).After treatment,the study group had N-terminal pro-brain natriuretic peptide of(828.34±179.40)ng/L and cardiac troponin I of(2.60±0.69)μg/L,which were lower than(970.25±112.32)ng/L and(4.50±0.75)μg/L in the control group(P<0.05).There was no difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combined treatment of rhBNP and SMLI in CHF patients has definite curative effect,and can effectively improve the heart function of patients,adjust the serological indexes of heart failure,and has ideal safety and clinical application value.

Recombinant human brain natriuretic peptideSalviae miltiorrhizae and ligustrazine hydrochloride injectionChronic heart failureEfficacy

李凤玉

展开 >

277101 山东国欣颐养集团枣庄医院药材科

重组人脑利钠肽 丹参川芎嗪注射液 慢性心力衰竭 疗效

2024

中国现代药物应用
中国水利电力医学科学技术学会

中国现代药物应用

影响因子:0.862
ISSN:1673-9523
年,卷(期):2024.18(12)